ClinicalTrials.gg
CompletedNCT00962871Updated Feb 8, 2016Results posted

A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both

A Phase 1 interventional study of peginterferon alfa-2a [Pegasys] and tenofovir in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 6 sites in 4 countries. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2016-02-08.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.

Enrollment
49th of 59
30 · median 114
Started
2009
with 5 others
Phase 1
6 of 59
1 open now
Registered
17th of 59
by date
Lead sponsor
22 of 59
Hoffmann-La Roche

Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 49th largest by enrollment, is one of 6 that started in 2009, is one of 6 in phase 1, and was the 17th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 55 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This open-label, randomized, parallel-arm study will assess the early immunologic response in treatment-naïve Asian male patients with chronic hepatitis B after initiation of treatment with Pegasys or tenofovir or Pegasys plus tenofovir. Patients will be randomized to one of 4 cohorts to receive either Pegasys (360mcg subcutaneously weekly) or tenofovir (300mg orally daily) or both or no treatment for 2 weeks. After 2 weeks on study treatment, patients may opt to receive standard of care treatment with Pegasys. Target sample size is \<50.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male adults of Southeast and/or East Asian origin, 18-55 years of age
  • HBeAg-positive chronic
  • detectable HBV DNA

Exclusion criteria

Exclusion Criteria:

  • prior antiviral therapy for chronic
  • evidence of bridging fibrosis, cirrhosis or decompensated liver disease
  • positive test at screening for HAV (IgM), , HDV or
  • history or evidence of medical condition associated with chronic liver disease
  • antineoplastic or immunomodulatory treatment \</=6 months prior to first dose of study drug
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    1

    Drug: tenofovir

  • Experimental
    2

    Drug: peginterferon alfa-2a [Pegasys] · Drug: tenofovir

  • Experimental
    3

    Drug: peginterferon alfa-2a [Pegasys]

  • No intervention
    4

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Viral Quantitative e Antibody

    An acute virologic response was determined by change from baseline in viral antigen/antibody laboratory data.

    Time frame: Day 1, 3, 5, 8, 10, 14, Week 3, 4, 5, 6 (weeks are computed from the first dose of Pegasys)

Secondary outcomes

  1. Mean Change From Baseline in HBV-DNA log10

    An acute virologic response was determined by change from baseline in HBV-DNA log10.

    Time frame: Day 1, 3, 5, 8, 10, 14, Week 3, 4, 5, 6 (weeks are computed from the first dose of Pegasys)

  2. Early Changes in Viral Sequence Associated With Viral Suppression

    Viral sequence data was obtained from the first 10 participants enrolled in Study but on analysis of the data, numerous low frequency deviations from the HBV consensus sequences were observed in the 454 SLX sequence data which were not replicated in data obtained from routine Sanger sequencing. These sequence deviations did not correspond to a temporal pattern consistent with selection of mutations following HBV treatment. Moreover, they could not be reliably distinguished from sequencing artifacts. It was also revealed that complete genome coverage was not obtained due to errors in the design of the primer sequences. For these reasons, further sequence analyses were not performed for the remaining treatment population.

    Time frame: Day 1, 5, 14, Week 4 and 6

07

Results

Posted Jan 13, 2016

Participant flow

The study was conducted between 30 July 2009 to 01 February 2012 and recruited participants from 4 centers in New Zealand (1), Taiwan (1), and Singapore (2).

Participant flow — Overall Study
MilestoneTenofovir 300 mgTenofovir 300 mg + PEG-IFN Alfa-2a 360 μgPEG-IFN Alfa-2a 360 μgDelayed Treatment
Started66126
Completed66126
Not completed0000

Outcome measures

PrimaryMean Change From Baseline in Viral Quantitative e Antibody

An acute virologic response was determined by change from baseline in viral antigen/antibody laboratory data.

Time frame:
Day 1, 3, 5, 8, 10, 14, Week 3, 4, 5, 6 (weeks are computed from the first dose of Pegasys)
Reported as:
Mean · Cut-off index (C.O.I.)
Mean Change From Baseline in Viral Quantitative e Antibody
Cut-off index (C.O.I.)Tenofovir 300 mgTenofovir 300 mg + PEG-IFN Alfa-2a 360 μgPEG-IFN Alfa-2a 360 μgDelayed Treatment
Day 10.07 ± 0.1620.15 ± 0.2340.02 ± 0.0630.03 ± 0.062
Day 30.00 ± 0.0890.03 ± 0.267-0.13 ± 0.119-0.10 ± 0.274
Day 5-0.02 ± 0.0490.04 ± 0.255-0.15 ± 0.1500.07 ± 0.066
Day 8-0.05 ± 0.0510.07 ± 0.223-0.09 ± 0.1550.04 ± 0.069
Day 10-0.13 ± 0.1460.04 ± 0.247-0.12 ± 0.1750.03 ± 0.127
Day 14-0.02 ± 0.1470.03 ± 0.259-0.13 ± 0.267-0.00 ± 0.162
Week 3NA ± NA0.01 ± 0.219-0.22 ± 0.282NA ± NA
Week 4-0.04 ± 0.302-0.05 ± 0.370-0.29 ± 0.322-0.40 ± 0.521
Week 6NA ± NA-0.21 ± 0.785-0.31 ± 0.481NA ± NA
SecondaryMean Change From Baseline in HBV-DNA log10

An acute virologic response was determined by change from baseline in HBV-DNA log10.

Time frame:
Day 1, 3, 5, 8, 10, 14, Week 3, 4, 5, 6 (weeks are computed from the first dose of Pegasys)
Reported as:
Mean · IU/mL
Mean Change From Baseline in HBV-DNA log10
IU/mLTenofovir 300 mgTenofovir 300 mg + PEG-IFN Alfa-2a 360 μgPEG-IFN Alfa-2a 360 μgDelayed Treatment
Day 2-0.61 ± 0.330-0.46 ± 0.196-0.14 ± 0.1790.08 ± 0.110
Day 3-1.04 ± 0.342-0.75 ± 0.480-0.46 ± 0.2220.04 ± 0.064
Day 5-1.53 ± 0.306-1.45 ± 0.551-0.64 ± 0.239-0.06 ± 0.120
Day 8-2.16 ± 0.244-1.93 ± 0.645-0.54 ± 0.226-0.07 ± 0.316
Day 10-2.37 ± 0.167-2.11 ± 0.735-0.57 ± 0.299-0.09 ± 0.493
Day 14-2.7 ± 0.142-2.46 ± 0.800-0.61 ± 0.521-0.26 ± 0.573
Week 3-0.76 ± 0.518-2.88 ± 0.702-0.79 ± 0.622-1.80 ± 0.866
Week 4-0.84 ± 0.422-1.49 ± 0.652-0.98 ± 0.772-2.17 ± 0.871
Week 5NA ± NA-1.37 ± 0.923-1.22 ± 0.819NA ± NA
Week 6NA ± NA-1.73 ± 1.462-1.30 ± 0.978NA ± NA
SecondaryEarly Changes in Viral Sequence Associated With Viral Suppression

Viral sequence data was obtained from the first 10 participants enrolled in Study but on analysis of the data, numerous low frequency deviations from the HBV consensus sequences were observed in the 454 SLX sequence data which were not replicated in data obtained from routine Sanger sequencing. These sequence deviations did not correspond to a temporal pattern consistent with selection of mutations following HBV treatment. Moreover, they could not be reliably distinguished from sequencing artifacts. It was also revealed that complete genome coverage was not obtained due to errors in the design of the primer sequences. For these reasons, further sequence analyses were not performed for the remaining treatment population.

Time frame:
Day 1, 5, 14, Week 4 and 6

Results for this outcome have not been posted.

Adverse events

Collected over Up to Week 6. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tenofovir 300 mg—0/6 (0%)6/6 (100%)
Tenofovir 300 mg + PEG-IFN Alfa-2a 360 μg—0/6 (0%)6/6 (100%)
PEG-IFN Alfa-2a 360 μg—0/12 (0%)12/12 (100%)
Delayed Treatment—0/6 (0%)6/6 (100%)
Most frequent other events
Showing 10 of 55
Most frequent other events
EventTenofovir 300 mgTenofovir 300 mg + PEG-IFN Alfa-2a 360 μgPEG-IFN Alfa-2a 360 μgDelayed Treatment
PyrexiaGeneral disorders0/65/69/123/6
HeadacheNervous system disorders1/65/66/124/6
MyalgiaMusculoskeletal and connective tissue disorders0/60/65/122/6
FatigueGeneral disorders2/62/64/122/6
Back painMusculoskeletal and connective tissue disorders0/62/62/121/6
NauseaGastrointestinal disorders0/62/60/120/6
NeutropeniaBlood and lymphatic system disorders0/61/63/122/6
LethargyNervous system disorders1/61/63/121/6
Decreased appetiteMetabolism and nutrition disorders0/60/63/120/6
Influenza like illnessGeneral disorders1/60/61/121/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tenofovir 300 mgTenofovir 300 mg + PEG-IFN Alfa-2a 360 μgPEG-IFN Alfa-2a 360 μgDelayed TreatmentTotal
<=18 years00000
Between 18 and 65 years6612630
>=65 years00000
Age, Continuous
Age, Continuous(years)Tenofovir 300 mgTenofovir 300 mg + PEG-IFN Alfa-2a 360 μgPEG-IFN Alfa-2a 360 μgDelayed TreatmentTotal
Mean37.8 ± 11.0928 ± 3.1628.5 ± 5.4027.2 ± 3.8730 ± 7.26
Sex: Female, Male
Sex: Female, Male(Participants)Tenofovir 300 mgTenofovir 300 mg + PEG-IFN Alfa-2a 360 μgPEG-IFN Alfa-2a 360 μgDelayed TreatmentTotal
Female00000
Male6612630
08

Study locations

6 sites
  • Los Angeles, California 90036, United States
  • San Francisco, California 94143-0538, United States
  • Grafton, 1010, New Zealand
  • Singapore, 119228, Singapore
  • Singapore, 169608, Singapore
  • Taipei, 100, Taiwan
09

References and documents

Publications

  • Mehrotra A, D'Angelo JA, Romney-Vanterpool A, Chu T, Bertoletti A, Janssen HLA, Gehring AJ. IFN-alpha Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T-Cell Proliferation. J Infect Dis. 2020 Jun 16;222(1):148-157. doi: 10.1093/infdis/jiaa064. PubMed 32049318 ↗
  • Hong LZ, Hong S, Wong HT, Aw PP, Cheng Y, Wilm A, de Sessions PF, Lim SG, Nagarajan N, Hibberd ML, Quake SR, Burkholder WF. BAsE-Seq: a method for obtaining long viral haplotypes from short sequence reads. Genome Biol. 2014;15(11):517. doi: 10.1186/PREACCEPT-6768001251451949. PubMed 25406369 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2009
First posted
Aug 20, 2009
Start
Aug 2009
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Jan 13, 2016
Last update
Feb 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00962871
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 20, 2009
Start date
Aug 2009
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Jan 13, 2016
Last update
Feb 8, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Tenofovir

Start the discussion